Cellular hysteresis as a principle to maximize the efficacy of antibiotic therapy

Roderich Roehmholdt, Chaitanya S. Gokhale, Philipp Dirksen, Christopher Blake, Philip Rosenstiel, Arne Traulsen, Dan I. Andersson, and Hinrich Schulenburg

Antibiotic resistance has become one of the most dramatic threats to global health. While novel treatment options are urgently required, most attempts focus on finding new antibiotic substances. However, their development is costly, and their efficacy is often compromised within short time periods due to the enormous potential of microorganisms for rapid adaptation. Here, we developed a strategy that uses the currently available antibiotics. Our strategy exploits cellular hysteresis, which is the long-lasting, transient, directional change in cellular physiology that is induced by one antibiotic and sensitizes bacteria to another subsequently administered antibiotic. Using evolution experiments, mathematical modeling, genomics, and functional genetic analysis, we demonstrate that sequential treatment protocols with high levels of cellular hysteresis constrain the evolving bacteria by (i) increasing extinction frequencies, (ii) reducing adaptation rates, and (iii) limiting emergence of multidrug resistance. Cellular hysteresis is most effective in fast sequential protocols, in which antibiotics are changed within 12 h or 24 h, in contrast to the less frequent changes in cycling protocols commonly implemented in hospitals. We found that cellular hysteresis imposes specific selective pressure on the bacteria that disfavors resistance mutations. Instead, if bacterial populations survive, hysteresis is countered in two distinct ways, either through a process related to antibiotic tolerance or a mechanism controlled by the previously uncharacterized two-component regulator CpxS. We conclude that cellular hysteresis can be harnessed to optimize antibiotic therapy, to achieve both enhanced bacterial elimination and reduced resistance evolution.

N
atural environments are often temporarily dynamic. They produce continuously changing selective constraints that are a particular challenge for organisms to adapt to (1). Similar dynamic conditions may be used in human therapy to limit the ability of pathogens for resistance evolution. Antibiotic resistance is a global threat (2), enhanced by the ongoing emergence of new resistance mechanisms (3, 4). Sequential treatments may be one option to counter emerging resistance: The alternation of antibiotics may produce continuously changing selective constraints that are observed with PhoQ/PhoP (15). Upon specific environmental change, these inherited responses can have deleterious fitness effects. For example, salt-induced expression of the PhoE porin increases sensitivity to acid (16). Furthermore, structural damage from past stress encounters may be amplified in new environments. We here use the term “cellular hysteresis” (17) to summarize the inducible and long-lasting physiological effects on cellular integrity and function, spanning both discrete and quantitative changes. The term is more general than phenotypic memory, as it comprises positive and negative fitness effects induced by previous exposures. Although cellular hysteresis likely determines pathogen survival during sequential antibiotic treatments, it is not part of current treatment concepts. Consideration of negative hysteresis may enhance treatment efficacy when exposure to one antibiotic temporarily increases susceptibility to a subsequently administered second antibiotic.

Significance

Rapid evolution is central to the current antibiotic crisis. Sustainable treatments must thus take account of the bacteria’s potential for adaptation. We identified cellular hysteresis as a principle to constrain bacterial evolution. Cellular hysteresis is a persistent change in bacterial physiology, reminiscent of cellular memory, which is induced by one antibiotic and enhances susceptibility toward another antibiotic. Cellular hysteresis increases bacterial extinction in fast sequential treatments and reduces selection of resistance by favoring responses specific to the induced physiological effects. Fast changes between antibiotics are key, because they create the continuously high selection conditions that are difficult to counter by bacteria. Our study highlights how an understanding of evolutionary processes can help to outsmart human pathogens.


The authors declare no conflict of interest.

This article is a PNAS Direct Submission. S.B. is a guest editor invited by the Editorial Board.

This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

Data deposition: The sequences reported in this paper have been deposited in the NCBI Sequence Read Archive (SRA) database, https://www.ncbi.nlm.nih.gov/sra (Bioproject no. PRJNA484297).

1To whom correspondence should be addressed. Email: hsvon@evolbio.mpg.de.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1810004115/-/DCSupplemental.

Published online September 12, 2018.

www.pnas.org/cgi/doi/10.1073/pnas.1810004115

PNAS | September 25, 2018 | vol. 115 | no. 39 | 9767–9772
The objectives of our study were to test the potential of negative hysteresis to enhance efficacy of sequential therapy. We used the pathogen *Pseudomonas aeruginosa* as a model—the second-most critical threat of a multidrug-resistant pathogen (18). We first characterized the hysteresis landscape for *P. aeruginosa* for three clinically relevant, bactericidal antibiotics with distinct cellular targets: ciprofloxacin (CIP), gentamicin (GEN), and carbenicillin (CAR). We then investigated how different levels of cellular hysteresis modulate the evolutionary adaptive response to sequential treatment using high-throughput experimental evolution, mathematical modeling, whole-genome sequencing, and functional genetic analysis of potential targets of selection. Finally, we validated the potential of antibiotic hysteresis for the inhibition and prediction of resistance evolution by second-order experimental evolution.

**Results and Discussion**

**Cellular Hysteresis Depends on the Order of Drug Switches.** We determined how short exposures to nonlethal concentrations of the three considered antibiotics CIP, GEN, and CAR affected later antibiotic treatment, by performing time-kill experiments (Fig. 1A). The inferred hysteresis landscape included negative, positive, and neutral effects and showed strong directionality. For the drug pair CAR/GEN, the sign of hysteresis effects was dependent on drug order (Fig. 1B): Preexposure to GEN, which is known to cause translational stress, protected cells from killing by CAR, while preexposure to CAR, which causes cell envelope stress, increased bactericidal activity of GEN (Fig. 1A–C and Movie S1). Similar directionality was observed for the drug pair CIP/GEN (Fig. 1B). Neutral or mild hysteresis effects were observed for the pair CIP/CAR. Altogether, the hysteresis landscape indicated that population survival during the antibiotic switch is strongly history-dependent, thus emphasizing the importance of drug order for the design of effective treatment. Order dependence and the observation that negative hysteresis can be achieved with drug pairs known to interact either synergistically (GEN+CAR) or antagonistically (CIP+GEN) (19) demonstrate that hysteresis and drug interaction are not necessarily linked. Hysteresis is also distinct from collateral sensitivity, as it occurs immediately, i.e., without acquiring resistance mutations.

Further analysis of negative hysteresis caused by the CAR → GEN switch revealed that pretreatments as short as 15 min (equivalent to 1/3 generation time) and concentrations as low as 3 μg/mL [1/32 of the minimal inhibitory concentration (MIC)] were sufficient for the induction of accelerated killing (Fig. 1D and Movie S2). The bactericidal activity increased 400-fold when the 15-min pretreatments were performed with higher concentrations, i.e., 2× MIC. These findings indicate a specific and robust physiological effect that may be exploited to increase the efficacy of antibiotic therapy, for example, by using sequential treatment. The increased killing is likely explained by β-lactam–induced acceleration of cellular influx of the aminoglycoside (20). The reduced killing in the reversed direction may be explained by aminoglycoside-induced up-regulation of efflux pumps (21, 22).

**Negative Hysteresis Increases Treatment Efficacy and Constrains Evolution of Resistance.** By modulating bacterial killing, we hypothesized that cellular hysteresis influences the rate of resistance evolution during sequential treatment dependent on drug order and the resulting cumulative level of hysteresis. To test these predictions, we conducted a high-throughput evolution experiment with 190 replicate populations over a total of 96 transfers (each with 12-h growth intervals; total of ~500 generations; Fig. 2A and SI Appendix, Fig. S2). We included three main types of sequential protocols to disentangle the influence of hysteresis from the frequency and regularity of drug switches (Fig. 2B, columns 1–3). Evolutionary dynamics were tightly monitored, with continuous measurements of population growth (every 15 min). These measurements revealed that the evolutionary dynamics were separated into three main phases across the 96 transfers (Fig. 3A): (i) an initial phase up to roughly transfer 12, during which populations adapted rapidly and treatments varied strongly in evolutionary dynamics; (ii) an optimization phase from transfer 12 up to approximately transfer 48, during which two treatments (monotherapy, slow regular protocol) were almost fully adapted, while the other two (fast regular and random protocols) still produced increases in growth, yet at lower rates as during the first phase; and (iii) the long-term dynamics from transfer 48 onward, during which only small growth increases and little variation among treatments were observed. For a more detailed analysis, we focused on the early dynamics up to transfer 12, because these encompass the strongest differences in the tested variables and cover a clinically relevant time period of 6 d.

For the early dynamics, fast and random sequences led to significant improvements in three independently characterized, complementary measures for treatment efficiency (Fig. 2B; see SI Appendix. Tables S1–S6 for statistics), including (i) higher extinction frequencies (inferred from absence of growth during experimental evolution), (ii) lower adaptation rates (calculated from growth characteristics measured during the evolution experiment), and (iii) lower levels of evolved multidrug resistance (MDR, determined from antibiotic dose–response curves for individual bacterial clones isolated from the evolving populations; SI Appendix, Fig. S3). Importantly, the cumulative
levels of hysteresis were significantly correlated to both adaptation rates and evolved MDR (Spearman rank correlation, ρ ≥ 0.73, P ≤ 0.01; Fig. 2C). Evolved MDR was also significantly associated with switching rate, but to a lesser degree (Spearman rank correlation, ρ = 0.66, P = 0.019), while there was no significant relationship between switching and adaptation rates (SI Appendix, Fig. S3). Increases in both negative hysteresis level and switching rate led to higher extinction frequencies, even though the effect was not statistically significant. We conclude that, even though switching rate is important, the consideration of negative hysteresis is sufficient to predict treatment efficacy.

Surprisingly, the fast sequential protocols resulted in significantly fewer resistance types and thus less genotypic diversity than the slow regular treatments (Figs. 2B and 3B and SI Appendix, Fig. S4 and Table S3). These findings contrast with expectations from population genetic theory, because fast switching should have prevented competitive exclusion and, instead, caused coexistence of multiple types that continuously varied in relative frequency parallel to antibiotic exposure. To assess these dynamics, we developed and analyzed a mathematical model tailored to the design of the evolution experiment. Under standard conditions (without hysteresis), the model indeed predicted coexistence of several types under fast sequential conditions (Fig. 2D and SI Appendix, Fig. S6). Importantly, when we added hysteresis effects to the model, we found increased selection pressure and a reduction of diversity, especially for the fast and random sequential protocols. These observations suggest that the inducible physiological effects act as a strong selective constraint during sequential treatment and influence diversity within the evolving populations.

The mathematical model indicated that negative hysteresis increases selection intensity (Fig. 2D), yet the observed outcome was not MDR—as would be expected from competitive release (23)—but rather a constrained ability to evolve MDR (Fig. 2B). Thus, we hypothesized that negative hysteresis selects for traits specifically directed against the inducible physiological effects rather than resistance. This idea was supported by our additional analysis of growth rate. Almost all drug protocols resulted in significantly reduced growth rates under drug-free conditions (Fig. 2B, last column), but the three sequences (#5, #12, #15) with high levels of negative hysteresis and almost no evolved MDR showed the strongest growth reductions of up to 41%. The combination of reduced growth and no MDR is indicative of antibiotic tolerance (24), an evolutionary strategy, in which bacteria evade killing by slow growth and which could have been favored through selection by negative hysteresis.

**Negative Hysteresis Favors Genetic Changes Mediating Tolerance and an Unknown Response.** To further assess the selective impact of negative hysteresis, we characterized the genes that have likely been the targets of selection using whole-genome sequencing and functional genetic analysis. The genomic characterization identified different sets of mutations to be favored by the main treatment types (Fig. 4 and Dataset S1). Intriguingly, the single nonresistant isolate from protocol #12 harbored a mutation that mediated a phenotypic response related to antibiotic tolerance. In detail, we followed concepts and methodology described previously (25), to test for tolerance with the help of time-kill experiments. These experiments revealed absence of resistance but reduced killing on all three antibiotics (Figs. 3B and 5B and SI Appendix, Table S7), consistent with antibiotic tolerance. This isolate had two mutations, a point mutation in the *ispA* gene (leading to amino acid change Y249D) and a frame shift in the *gsvT2* gene. Because the *gsvT2* mutation occurred across treatment groups (Fig. 4A), the *ispA* mutation is likely the adaptive change that caused reduced growth, possibly due to the toxic accumulation of isoprenyl diphasphates, as previously recorded for a Δ*ispA* *E. coli* mutant (26). Sequence #12 was enriched for CAR-induced sensitization toward GEN (Fig. 24). A reassessment of the CAR → GEN transition showed that bacterial cells of this isolate could no longer be sensitized (Fig. 5C). We conclude that, in this single case, selection by negative hysteresis in sequence #12 has likely been countered by the emergence of a process related to antibiotic tolerance, mediated through a mutation in *ispA*.

In several other fast sequential protocols, negative hysteresis was countered by mutations in *cpxS* (SI Appendix, Fig. S7). This gene is related to the *E. coli* envelope stress response system *CpxA–CpxR*, which is activated by misfolded proteins, as caused by aminoglycosides (27), and involved in intrinsic resistance to these drugs in *E. coli* (28). Mutations in *cpxS* were significantly enriched in fast sequential treatments (SI Appendix, Table S6), including those with little indication of antibiotic tolerance (e.g., normal growth under drug-free conditions; protocol #7; Fig. 2B). To explore its function, we reintroduced one prevalent *cpxS*
mutation (leading to T163P) into the ancestral background and compared it to the ancestor and the similarly generated mexR (T130P) mutant as a control. MexR regulates the multidrug efflux pump MexAB-OprM, which can extrude different drug classes (29), potentially conferring MDR. MexR mutations are unlikely favored by negative hysteresis, as this gene was frequently and exclusively mutated in slow sequential treatments (Fig. 4A). Our analysis revealed that resistance against CIP and CAR was moderate for the mexS mutant, while neither mutation altered resistance against CIP and CAR hysteresis for defined mutants in mexA, nalC, and nalD, all affecting the MexAB-OprM multidrug efflux system. Despite their increased resistance to the antibiotic of the pretreatment (i.e., CAR), negative hysteresis and thus enhanced killing by GEN could be readily induced, with high (up to 600 μg/mL) and also subinhibitory doses (SI Appendix, Fig. S10). We conclude that bacteria can suffer from negative hysteresis even if they are resistant against the drug of the sensitizing pretreatment.

**An Independent Experimental Test Validates the Importance of Negative Hysteresis.** To specifically test the consequences of negative hysteresis, we took inspiration from Lewontin’s theoretical work on evolutionary historicity (30), which highlighted that the order of events influences the evolutionary outcome. We thus repeated evolution experiments with the reversed order of drugs for the most effective sequence, #12, and the least effective sequence, #13 (inferred from evolved MDR; Fig. 2B). The reverse sequences had the same drug proportions and number of switches as the original sequences, but the direction of transitions was opposite. As a consequence, all was equal except that the cumulative level of negative hysteresis was decreased by 10% in the first case and increased by 11% in the second case (Fig. 6A). As expected, reversing #12 decreased extinction frequency (Fig. 6B) and significantly increased resistance (Fig. 6C and SI Appendix, Fig. S9). In conclusion, mutations in mexS were favored in several fast sequential protocols and are thus likely to represent a general response to selection by negative hysteresis, apparently independent of antibiotic tolerance.

The above result for the mexR mutant additionally suggests that canonical resistance mechanisms do not abolish negative hysteresis. To further test this point, we characterized CAR → GEN hysteresis for defined mutants in mexA, nalC, and nalD, all affecting the MexAB-OprM multidrug efflux system. Despite their increased resistance to the antibiotic of the pretreatment (i.e., CAR), negative hysteresis and thus enhanced killing by GEN could be readily induced, with high (up to 600 μg/mL) and also subinhibitory doses (SI Appendix, Fig. S10). We conclude that bacteria can suffer from negative hysteresis even if they are resistant against the drug of the sensitizing pretreatment.

**An Independent Experimental Test Validates the Importance of Negative Hysteresis.** To specifically test the consequences of negative hysteresis, we took inspiration from Lewontin’s theoretical work on evolutionary historicity (30), which highlighted that the order of events influences the evolutionary outcome. We thus repeated evolution experiments with the reversed order of drugs for the most effective sequence, #12, and the least effective sequence, #13 (inferred from evolved MDR; Fig. 2B). The reverse sequences had the same drug proportions and number of switches as the original sequences, but the direction of transitions was opposite. As a consequence, all was equal except that the cumulative level of negative hysteresis was decreased by 10% in the first case and increased by 11% in the second case (Fig. 6A). As expected, reversing #12 decreased extinction frequency (Fig. 6B) and significantly increased resistance (Fig. 6C and SI Appendix, Fig. S9). In conclusion, mutations in mexS were favored in several fast sequential protocols and are thus likely to represent a general response to selection by negative hysteresis, apparently independent of antibiotic tolerance.

The above result for the mexR mutant additionally suggests that canonical resistance mechanisms do not abolish negative hysteresis. To further test this point, we characterized CAR → GEN hysteresis for defined mutants in mexA, nalC, and nalD, all affecting the MexAB-OprM multidrug efflux system. Despite their increased resistance to the antibiotic of the pretreatment (i.e., CAR), negative hysteresis and thus enhanced killing by GEN could be readily induced, with high (up to 600 μg/mL) and also subinhibitory doses (SI Appendix, Fig. S10). We conclude that bacteria can suffer from negative hysteresis even if they are resistant against the drug of the sensitizing pretreatment.

A map of the cellular functions targeted by selective adaptation is shown in Fig. 6B. Resistance is mostly achieved by mutations in two-component regulators or transcriptional regulators that control efflux pumps. AG, aminoglycosides; BL, β-lactams; FQ, fluoroquinolones; PMF, proton motive force.

**Genetic Basis of Adaptation.** (A) Overlap of mutated genes among treatment types. Typeface and boldness indicate number of mutations in a gene. (B) Schematic of cellular functions targeted by adaptive evolution. Resistance is mostly achieved by mutations in two-component regulators or transcriptional regulators that control efflux pumps. AG, aminoglycosides; BL, β-lactams; FQ, fluoroquinolones; PMF, proton motive force.

---

**Fig. 3.** Overall evolutionary dynamics in response to sequential treatment. (A) Evolutionary dynamics expressed as total growth relative to evolving untreated controls. Mean ± 2 SEM, n = 3 to 6 protocols per treatment with 12 replicate populations, extinct lineages excluded. Dashed vertical lines indicate time points for isolation of evolved bacterial clones. (B) Resistance profiles of 320 clones isolated after transfer 12 from 16 populations (early isolates) and 320 clones isolated after transfer 48 (late isolates); the clones are indicated by bars within the boxes for a particular treatment. Pie charts indicate frequencies of phenotypic subpopulations, as determined by hierarchical clustering. Different colors denote the distinct types per population. Summary statistics are presented in Fig. 2.

---

**Fig. 4.** Genetic basis of adaptation. (A) Overlap of mutated genes among treatment types. Typeface and boldness indicate number of mutations in a gene. (B) Schematic of cellular functions targeted by adaptive evolution. Resistance is mostly achieved by mutations in two-component regulators or transcriptional regulators that control efflux pumps. AG, aminoglycosides; BL, β-lactams; FQ, fluoroquinolones; PMF, proton motive force.
Our results show that antibiotics can induce long-lasting changes in bacterial physiology that enhance or inhibit the bactericidal activity of other antibiotics, thereby revealing a principle, cellular hysteresis, that can be exploited to optimize antibiotic therapy. Cellular hysteresis can still act in bacteria that are resistant against the pretreatment drug, highlighting its clinical potential, although resistance was not affected, most likely because only few populations survived and could be used for resistance analysis. These results demonstrate that cellular hysteresis can determine the efficacy of sequential therapy.

Conclusions
Our results show that antibiotics can induce long-lasting changes in bacterial physiology that enhance or inhibit the bactericidal activity of other antibiotics, thereby revealing a principle, cellular hysteresis, that can be exploited to optimize antibiotic therapy. Cellular hysteresis can still act in bacteria that are resistant against the pretreatment drug, highlighting its clinical potential, although resistance was not affected, most likely because only few populations survived and could be used for resistance analysis. These results demonstrate that cellular hysteresis can determine the efficacy of sequential therapy.

Materials and Methods
Material. P. aeruginosa UCBPP-PA14 (34) was grown at 37 °C in M9 medium supplemented with glucose (2 g/L), citrate (0.5 g/L), casamino acids (1 g/L), and an antibiotic, as indicated.

Time-Kill Experiments. Exponential phase cells (5 × 10^6 cfu/mL) were pretreated with sublethal antibiotic concentrations for the indicated time. The medium was exchanged to expose cells to a second antibiotic at IC_50, followed by cfu counting for 6 h. Hysteresis effects were quantified as the average log_10 difference in cfu counts of pretreated and control cultures. Negative pretreatment and control cultures were separately incubated in untreated parallel cultures. Each set was sampled by hysteresis analysis. Bacterial killing was confirmed by time-lapse microscopy, monitoring bacteria on agarose pads (35) using a Zeiss LSM 700.

Dose-Response Curves. A standardized inoculum (5 × 10^6 cfu) was incubated with defined antibiotic concentrations in 96-well plates for 12 h at 37 °C, followed by optical density measurements at 600 nm (OD_600).

Main Evolution Experiment. We performed serial dilution evolution experiments (6, 23, 36) and selection with 16 different antibiotic sequences (see also SI Appendix). Sequences #1 to #4 had constant environments. Sequences #5 to #16 contained equal frequencies of CIP, GEN, and CAR, but differed in hysteresis levels, due to drug order and switching rate. Each treatment had 12 replicates (founded with 5 × 10^7 cells from six independent PA14 starting cultures) and 96 serial transfers (2% transfer volume), each separated by 12 h. Antibiotic selection was applied at IC_50 in 96-well plates, and growth was monitored by OD_600 every 15 min (EON; BioTek Instruments; 180-rpm double orbital shaking). Evolved material was conserved at −80 °C in 10% (vol/vol) DMSO. Resistance evolution was assessed using the integral of the growth curve divided by the integral for the untreated reference evolving in parallel (relative area under curve or relative biomass, Fig. 3). Low values denote sensitivity to treatment, a value of 1 uninhibited growth (dynamics for all populations are shown in SI Appendix, Fig. S11). Adaptation rate was calculated with a sliding window approach as X^−1, where X is the transfer at which the mean relative biomass of a sliding window of 12 transfers reaches 0.75 for the first time. This measure is comparable with the previously described rate of adaptation (36), defined for constant environments, yet not applicable to fluctuating environments, in which growth often oscillates. Extinction frequencies were determined at the end of the evolution experiment by counting cases unable to grow in drug-free media.

Characterization of Evolved Isolates. We measured antibiotic dose–response curves for 880 evolved isolates from evolved populations after transfers 12 and 48. Resistance profiles were obtained as in Dose–Response Curves, with concentrations from 1/8 MIC to 16× MIC, as assessed in the relative area of dose–response curve for isolates and corresponding ancestors measured on the same plates (SI Appendix, Fig. S3). For treatment comparisons, we defined MDR scores as the sum of resistance values on the three antibiotics. Subpopulations were identified by hierarchical clustering of resistance profiles. We characterized growth in drug-free medium. See SI Appendix.

Mathematical Model. We developed a deterministic model to explore the ability of different antibiotic protocols to limit population growth by the evolution of new ways for improving antibiotic therapy—using the available drugs in a rational and refined way.

Fig. 5. Evolutionary adaptation to negative hysteresis. (A) Evolved MDR of isolates from sequential treatments (top two bars) and corresponding reconstructed mutants (bottom bar). Mean ± SEM, n ≥ 3. (B) Isolate from sequential protocol #12 with mutation in ispA shows antibiotic tolerance and thus reduced cellular death during antibiotic exposure (in this case, CIP). (C) (Top) CAR-induced sensitization toward GEN (solid lines) inhibited growth in ancestor and mexR mutant but neither cpxS nor ispA mutants. Mean ± SEM, n = 6. (Bottom) Confirmation of results by measuring dead cells over time using flow cytometry. Mean ± SEM, n = 3. (D) Evolutionary adaptation to negative hysteresis. (A) Evolved MDR of isolates from sequential treatments (top two bars) and corresponding reconstructed mutants (bottom bar). Mean ± SEM, n ≥ 6. (B) Isolate from sequential protocol #12 with mutation in ispA shows antibiotic tolerance and thus reduced cellular death during antibiotic exposure (in this case, CIP). (C) (Top) CAR-induced sensitization toward GEN (solid lines) inhibited growth in ancestor and mexR mutant but neither cpxS nor ispA mutants. Mean ± SEM, n = 6. (Bottom) Confirmation of results by measuring dead cells over time using flow cytometry. Mean ± SEM, n = 3.
resistant types. We modelled growth competition (as a function of population size) and included mutation rate with density and growth rate. Each genotype had three growth rates, for each of the possible treatments, \( r_i = (\kappa_i^\text{CM} \cdot \nu_i) \) and growth rate \( r_i \) of the corresponding entry from table S5. The mutation rate \( q_i \) determined the change of genotype j to another genotype i. The carrying capacity was defined by \( K_i \). To simulate serial transfers, the mixture of types was diluted by a dilution factor \( DF \) at the end of each season. If the density of a genotype fell below the cutoff \( \kappa_i \) during dilution, it was lost and could only reappear via mutation. Following dilution, treatments could either switch or be repeated. The model was parameterized according to the evolution experiment: \( K = 10^6 \) cells, \( DF = 50 \) applied every 12 h, \( q = 10 \). Population size was \( K_i \) (IC\(_{50}\)) directly before the first transfer. Growth dynamics were generated for a simple system with four competing genotypes, the nonresistant wt and three mutants, individually resistant to CIP, GEN, or CAR, parameterized according to the results of the monotreatments \#1 to \#3 (growth rate table R, SI Appendix, Fig. S6). Some mutant growth rates were lower than those of the wt on particular antibiotics, denoting collateral sensitivity, consistent with previous results (37). Switches between antibiotics allowed for hysteretic effects, which we included by multiplying the respective growth rates from table R with the corresponding entry from table S, showing the antibiotic-induced physiological effects, experimentally inferred for the four genotypes (SI Appendix, Fig. S6). Using this model, we generated growth dynamics for mixed populations for the different sequential treatments, either with or without hysteresis. From the modeled dynamics, we inferred the selective pressure, as defined by \( K_{\text{sev}} \) and the within-population diversity, as calculated from Shannon entropy.

Genomics and Functional Genetic Analysis. Whole-genome sequencing was performed for 30 evolved isolates from different subpopulations at the early time point, and the three subpopulations of 8 at the late time point (SI Appendix). For defined mutants (SI Appendix), we assessed the change in growth upon pretreatment by OD\(_{600}\) every 15 min. We additionally used flow cytometry (Guava EasyCyte HT Blue-Green; Merck KGaA) with hourly samples, LiveDead staining, and three technical replicates. For staining, cells were incubated for 10 min with propidium iodide (P4170-25MG; Sigma-Aldrich) and thiazole orange (390062-250MG; Sigma-Aldrich). We assessed antibiotic tolerance for isolate 12-1a-E2-4 (isolated after transfer 12 from sequence \#12) via minimal duration of killing (25).

Replay Evolution Experiment. The experiment was performed as the main evolution experiment, using sequences \#12, \#12rev, \#13, \#13rev, and an untreated control. Sequences \#12 and \#13 were the same as the first 12 transfers in the main experiment, and \#12rev and \#13rev were their respective reverse sequences. Resistance was quantified by the fold changes in IC\(_{50}\).

Statistical Analyses. Data analysis was performed with R (38). Statistics, P values, and explanatory notes are provided in SI Appendix, Tables S1–S6.

Data Availability. The data are supplied as Datasets S1–S5. Sequence data are available from NCBI, BioProject PRJNA484297.

ACKNOWLEDGMENTS. We thank T. Bollenbach, T. Dagan, C. Eschenbrenner, F. Falush, M. Habig, A. Read, J. Rolff, M. Sixt, and the H.S. lab for advice; and H. Hemmerich, S. Stanisak, T. Naujoks, C. Noack, and M. Vollstedt from the Institute of Clinical Molecular Biology for DNA sequencing, as supported by the German Science Foundation Cluster of Excellence EXC 608. This research was funded by the German Science Foundation Grant SCHU 1415/12 (to H.S.), a Young Scientist Grant from the Zentrum Molekulare Biowissenschaften (Kiel; to R.R.), the International Max Planck Research School for Evolutionary Biology (R.R.), the Swedish Research Council (D.I.A.), the Leibniz Science Campus EvoLUNG (H.S.), and the Max-Planck Society (C.S.G., A.T., and H.S.).